The Molecular Taxonomy of Colorectal Cancer: What’s New?

Current Colorectal Cancer Reports

Volumn 11, Issue 3, 2015, Pages 118-124

  Sebio, Ana ^a,b   Lenz, Heinz Josef ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Classification; Colorectal; Molecular; Taxonomy

Indexed keywords

ADJUVANT CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CLONAL EVOLUTION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE MUTATION; HUMAN; INTESTINE CELL; METHYLATION; MICROSATELLITE INSTABILITY; MOLECULAR TAXONOMY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; TAXONOMY; TREATMENT RESPONSE;

EID: 84930199358     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-015-0267-4     Document Type: Review

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32.
4. Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signal. 2013;26(3):570–9.
5. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the apc/beta-catenin/tcf pathway in colorectal cancer. Cancer Res. 1998;58(6):1130–4.
6. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. Comprehensive evaluation of genetic alterations in colorectal cancers.
7. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266–73.
8. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816–9.
9. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363(6429):558–61.
10. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers. 2004;20(4–5):251–7.
11. Rudzki Z, Zazula M, Okon K, Stachura J. Low-level microsatellite instability colorectal carcinomas: do they really belong to a "gray zone" between high-level microsatellite instability and microsatellite-stable cancers? Int J Color Dis. 2003;18(3):216–21.
12. Wright CM, Dent OF, Newland RC, Barker M, Chapuis PH, Bokey EL, et al. Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut. 2005;54(1):103–8.
13. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and lynch syndrome. Histopathology. 2010;56(2):167–79.
14. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hmlh1 promoter correlates with lack of expression of hmlh1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57(5):808–11.
15. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N, et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res. 2002;62(21):6011–4.
16. Issa JP. Cpg island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988–93.
17. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, et al. Identification of differentially methylated sequences in colorectal cancer by methylated cpg island amplification. Cancer Res. 1999;59(10):2307–12.
18. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Cpg island methylator phenotype-low (cimp-low) in colorectal cancer: possible associations with male sex and kras mutations. J Mol Diagn JMD. 2006;8(5):582–8.
19. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. Cpg island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with braf mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.
20. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007;104(47):18654–9.
21. Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer. 2010;103(12):1875–84.
22. van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011;60(2):141–7.
23. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.
24. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(1):21–33.
25. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22(2):271–82.
26. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(3):609–18.
27. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863–75.
28. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.
29. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20):3219–26.
30. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of Folfox-based adjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(29):3664–72.
31. Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or folfiri in relation to microsatellite status: results of the petacc-3 trialdagger. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2015;26(1):126–32.
32. Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: Findings from nsabp c-08. J Natl Cancer Inst. 2013;105(13):989–92.
33. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. Cpg island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(8):2898–903.
34. Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the cpg island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol. 2008;13(6):498–503.
35. Shen L, Catalano PJ, Benson 3rd AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(20):6093–8.
36. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(15):3526–35.
37. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1564–71.
38. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(1):17–24.
39. Salazar R, de Waard JW, Glimelius B, Marshall J, Klaase J, Hoeven JVD, et al. The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (cc) patients using Coloprint. J Clin Oncol. 2012;30(suppl 4; abstr 678).
40. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(25):3937–44.
41. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(35):4611–9.
42. Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, et al. Validation of the 12-gene colon cancer recurrence score in nsabp c-07 as a predictor of recurrence in patients with stage ii and iii colon cancer treated with fluorouracil and leucovorin (fu/lv) and fu/lv plus oxaliplatin. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(36):4512–9.
43. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–8.
44. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–25.
45. Sadanandam A, Wang X, de Sousa EMF, Gray JW, Vermeulen L, Hanahan D, et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle. 2014;13(3):353–7.
46. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453.
47. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer J Int Cancer. 2014;134(3):552–62.
48. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231(1):63–76.
49. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genet. 2012;5:66.
50. Dienstmann R, Guinney J, Delorenzi M, De Reynies A, Roepman P, Sadanandam A, et al. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol. 2014;32:5s. suppl; abstr 3511.
51. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8.
52. Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40.
53. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of kras mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–6. Proof of principle showing how colorectal cancer can adapt and evolve influenced by the administered treatment.
54. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. Excellent review on cancer genomics.
55. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 2014;15(8):453.
56. Kopetz S, Overman MJCK, et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (MCRC). J Clin Oncol. 2014;32:5s (suppl; abstr 3509).
57. Pelizzola M, Ecker JR. The DNA methylome. FEBS Lett. 2011;585(13):1994–2000.
58. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.